TG Therapeutics, Inc. (TGTX) Dividend History

TG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of hematologic cancers and autoimmune diseases. The company’s portfolio includes agents aimed at addressing unmet medical needs in multiple sclerosis, B-cell malignancies, and other related conditions. Based in the United States, TG Therapeutics is engaged in both research and development efforts to bring innovative treatments to patients.

2 Gansevoort Street, 9th Floor, New York, NY, 10014
Phone: (212) 554-4484

Dividend History

TG Therapeutics, Inc. currently does not pay dividends

Company News

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics reported strong Q1 2025 financial results for its multiple sclerosis drug BRIUMVI, with $119.7 million in U.S. net sales and raised its full-year revenue guidance. The company also provided updates on its pipeline, including plans to advance subcutaneous BRIUMVI and a new therapy for progressive MS.

GlobeNewswire Inc.
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?

Several mid-cap stocks, including Bilibili, MARA Holdings, and ZEEKR Intelligent Technology, saw significant gains last week. The article highlights the top 8 mid-cap gainers and discusses the reasons behind their performance.

Benzinga

Featured Companies: ALGM MARA ON WLY WLYB
TG Therapeutics to Participate in the Evercore HealthCONx Conference

TG Therapeutics, a biopharmaceutical company, announced that its Chairman and CEO will participate in the 7th Annual Evercore HealthCONx Conference on December 3-5, 2024. The company has received FDA and European approvals for its multiple sclerosis treatment BRIUMVI.

GlobeNewswire Inc.
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

TG Therapeutics, a biopharmaceutical company, was ranked the fastest-growing company in North America on the 2024 Deloitte Technology Fast 500 list. This growth was driven by the success of their multiple sclerosis drug BRIUMVI, which was approved in 2022.

GlobeNewswire Inc.
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

The Motley Fool

Featured Companies: AAPL AMZN CAVA CHWY GLP IT MAN MANH MCD MNKD QCOM QRVO SNBR TGT VZ WOOF ZM

Dividend data last updated 06/07/2025 18:55:35 UTC